Café

© 2026 Longbridge｜Terms of Service Privacy Policy

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Unusual Whales

Aug 3, 2026 at 11:03 AM

Ocular is set to submit the NDA for AXPAXLI TM, targeting wet AMD, in Q4 2026 after a successful Type C Meeting with the U.S. FDA in May 2026.

Source: Unusual Whales The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Ocular Therap

OCUL.US

Open

--

High

--

Low

--

Prev Close

--

P/E^TTM

--

Market Cap

--

LongbridgeAI